daunorubicin has been researched along with carfilzomib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Adamcova, M; Brazdova, P; Hlavackova, M; Holzerova, K; Jansova, H; Jirkovska, A; Jirkovsky, E; Kolar, F; Kubes, J; Lencova-Popelova, O; Mazurova, Y; Pokorna, Z; Simunek, T; Sotakova-Kasparova, D; Sterba, M; Vostatkova, L | 1 |
2 other study(ies) available for daunorubicin and carfilzomib
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Topics: Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiotoxicity; Daunorubicin; Dose-Response Relationship, Drug; Male; Myocytes, Cardiac; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rabbits; Rats; Rats, Wistar | 2019 |